Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.56 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24576223 | 0.91 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL18415458 | 0.84 | MAPT (0.65) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5518470 | 0.84 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL22025937 | 0.84 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL16562080 | 0.84 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL16562180 | 0.83 | ALDH1A1 (0.69) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL4587584 | 0.83 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL17790723 | 0.83 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL27582701 | 0.83 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL17916794 | 0.83 | SMN1; SMN2 (0.88) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3189050-B1 | ANTIVIRAL AGENTS AND USES THEREOF | UNIV GRIFFITH (AU) | 2020-02-05 | — | — | EP | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| WO-2013084138-A1 | CYCLIC UREA DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | NPC1 4008/4885RAB9A 2816/4885SMN1; SMN2 4476/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | NPC1 4008/4885RAB9A 2816/4885SMN1; SMN2 4476/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | NPC1 4008/4885RAB9A 2816/4885SMN1; SMN2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.